Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. - Wikidata - awgldk - TriplyDB

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

http://www.wikidata.org/entity/Q33652742

about

Fifty years of melphalan use in hematopoietic stem cell transplantation High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

P2860

Q26824498-0D4F3993-7958-444C-859F-7B65C2EDE68E Q33566475-269CD654-DD74-4DF1-8237-6B0FA83DADC5 Q33828956-35C05961-1ED8-4CAB-9640-61BDA6B67512 Q33886267-32F62125-B02C-4162-9861-0664F08DB91D Q35057041-A05A3A9D-2C74-48F7-8FD8-3D2ED7C09470 Q35136563-08203850-DB17-4D71-8FD6-1A24F971BCC4 Q35705317-BB23ADAC-1F68-4D48-8900-C525AF7ACCCE Q36248964-6A8E1B3F-B98F-4E8D-A59A-73B9ACFE0BC2 Q36660672-5CA53EBE-0C37-426C-A745-24EE4A2ED6B1 Q37021454-A82196B9-CD48-4F24-91AE-584ADB8F8A23 Q37192391-A9D77A1C-65EE-46EA-B527-E7383CF91FC2 Q37738997-E88F430A-7A57-4A6F-8A72-F62FDBE41315 Q38102892-89402326-8209-4F57-84F4-B412E2C384DF Q38163027-4C116A1B-03B6-4B18-BB97-F01D139877CC Q38264356-1BED9BE3-BC37-46FA-8905-33508B794601 Q39212390-0DB0DAB4-FD78-4ED9-8D20-D03EACCD8076 Q41437866-E4F305C0-BD99-40C8-934B-551D5680F3C8 Q47369825-501CE91F-EA11-4641-AAC3-C4E30AAABADC

P2860

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

http://www.wikidata.org/entity/Q33652742

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Intravenous busulfan plus melp ...... dvanced lymphoid malignancies.

@ast

Intravenous busulfan plus melp ...... dvanced lymphoid malignancies.

@en

type

label

Intravenous busulfan plus melp ...... dvanced lymphoid malignancies.

@ast

Intravenous busulfan plus melp ...... dvanced lymphoid malignancies.

@en

prefLabel

Intravenous busulfan plus melp ...... dvanced lymphoid malignancies.

@ast

Intravenous busulfan plus melp ...... dvanced lymphoid malignancies.

@en

P1433

Q33652742-4C30840A-076C-4992-9262-D089569CDDD0

P1476

Q33652742-E225C3AD-6BAC-4F81-9749-3E5F964C37A2

P2093

Q33652742-018A85AB-195B-45C6-9534-49F0748F1842

Q33652742-1B48ED18-44CA-45F3-BABB-14895352D2AA

Q33652742-3AEDC794-60F5-4D52-9BF7-6E359CD07360

Q33652742-65F6E903-A65A-44B6-B5B9-379134E8BE66

Q33652742-6B3E8872-7B3E-4C13-8A18-A380758F2B80

Q33652742-7169F25A-1AD2-4DE5-A395-F84A50B2D5EC

Q33652742-94451ED0-99A8-4723-94C2-992EA4850491

Q33652742-A5A3EC74-326C-4520-BDDD-A48F0DE6EE23

Q33652742-B654405A-C20D-40CE-B77C-BC3A0E38C2E5

Q33652742-CA3CBD38-2591-44D7-847E-824FC377AD15

P2860

Q33652742-1C0379F7-146C-4A50-919C-632FCA5AEABB

Q33652742-216097B9-A620-42FE-AEEF-928836047F0D

Q33652742-27C35E40-3E02-468A-BCDB-D77F5B1210CC

Q33652742-2BD29FDB-982C-4C0E-9A57-FEAB2CB51453

Q33652742-2C080DCA-07CA-46FA-9F6C-34E0365E842E

Q33652742-31F4E57F-6393-4517-A92F-D2948D4BE7BA

Q33652742-373279D5-1851-473C-86F8-5813C5038A59

Q33652742-3DC31DE1-2D0D-4A2E-8A7B-6E48FE0E3C1F

Q33652742-41F1DB2D-5EE5-489A-A149-716EDFE07FF1

Q33652742-45409C79-64F2-4070-BAC0-2A88F38DAD88

P304

Q33652742-3EC0E365-52BB-4B4E-B8B9-5D13567DB189

P31

Q33652742-3FF047C9-3573-47AC-8E55-BD2FB71B06B3

P356

Q33652742-B35D0015-FC42-4FC8-9456-DD0BA10BAB56

P433

Q33652742-1EBB414F-80BB-479C-8D3D-B0D4486FF431

P478

Q33652742-B47DAA0E-74BD-4F1D-A873-E20289E551B9

P50

Q33652742-1139D2A0-E654-498D-B1D7-85C19E60B8FF

P577

Q33652742-EC84CB1A-BCFE-4364-B79A-765D07BE54E0

P698

Q33652742-8589300C-C236-410A-A3CF-49CB701B31BC

P932

Q33652742-128DD532-A811-4F41-96C5-84AE27C7DE54

P356

J.BBMT.2010.07.016

P1433

Biology of Blood and Marrow Transplantation

P1476

Intravenous busulfan plus melp ...... advanced lymphoid malignancies

@en

P2093

Borje S Andersson

http://www.w3.org/2001/XMLSchema#string

Celina Ledesma

http://www.w3.org/2001/XMLSchema#string

Elizabeth J Shpall

http://www.w3.org/2001/XMLSchema#string

Issa Khouri

http://www.w3.org/2001/XMLSchema#string

Muzaffar Qazilbash

http://www.w3.org/2001/XMLSchema#string

Partow Kebriaei

http://www.w3.org/2001/XMLSchema#string

Peter F Thall

http://www.w3.org/2001/XMLSchema#string

Reza Kazerooni

http://www.w3.org/2001/XMLSchema#string

Richard E Champlin

http://www.w3.org/2001/XMLSchema#string

Roy B Jones

http://www.w3.org/2001/XMLSchema#string

P2860

5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Cellular and clinical pharmacology of fludarabine.

Busulfan in hematopoietic stem cell transplantation

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.

P304

412-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2010.07.016

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20674757

http://www.w3.org/2001/XMLSchema#string

P932

4031688

http://www.w3.org/2001/XMLSchema#string